Ironwood Pharmaceuticals

Ironwood Initiates Ph III Study of Linaclotide in IBS-C
Ironwood Initiates Ph III Study of Linaclotide in IBS-C
CP Wire
Ironwood Pharmaceuticals
Allergan
linaclotide
Linzess
IBS-C
Flag link:
Ironwood Initiates Ph III Study of Linaclotide in IBS-C
Ironwood Pharmaceuticals
Allergan
linaclotide
Linzess
IBS-C
Flag link:
Ironwood’s preparation for activist-driven R&D split puts 40 staffers out of work
Ironwood’s preparation for activist-driven R&D split puts 40 staffers out of work
Fierce Pharma
Ironwood Pharmaceuticals
R&D
layoffs
Flag link:
Ironwood Pharma’s Sickle Cell Drug Gets Orphan Drug Designation
Ironwood Pharma’s Sickle Cell Drug Gets Orphan Drug Designation
BioSpace
Ironwood Pharmaceuticals
FDA
sickle cell disease
olinciguat
orphan drug
Flag link:
Ironwood pushing through mid-stage trials with nephropathy drug
Ironwood pushing through mid-stage trials with nephropathy drug
BioPharma Dive
Ironwood Pharmaceuticals
clinical trials
diabetic nephropathy
IW-1973
Flag link:
Allergan: Is Linzess 'Restasis 2.0'?
Allergan: Is Linzess 'Restasis 2.0'?
NY Shock Exchange
Allergan
Restasis
patents
Linzess
Ironwood Pharmaceuticals
Teva Pharmaceutical
IBS-C
Flag link:
Ironwood zeroes in on primary care doctors with new gout combo med Duzallo
Ironwood zeroes in on primary care doctors with new gout combo med Duzallo
Fierce Pharma
Ironwood Pharmaceuticals
gout
Duzallo
primary care
Flag link:
AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million
AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million
BioPharma Dive
AstraZeneca
Zurampic
Ironwood Pharmaceuticals
gout
Flag link:
Ironwood exec's brainstorm gives Allergan a marketing edge with Linzess
Ironwood exec's brainstorm gives Allergan a marketing edge with Linzess
Fierce Pharma Marketing
Ironwood Pharmaceuticals
Allergan
Linzess
Flag link:
Is This Ironwood Pharmaceuticals' Biggest Threat?
Is This Ironwood Pharmaceuticals' Biggest Threat?
Motley Fool
Ironwood Pharmaceuticals
Linzess
plecanatide
Synergy Pharmaceuticals
Flag link:
​Ironwood marks rare milestone: 1 million patients have taken Linzess
​Ironwood marks rare milestone: 1 million patients have taken Linzess
Bizjournals.com
Ironwood Pharmaceuticals
Linzess
IBS-C
Flag link:
3 Biotech Stocks That Are Getting a Heckuva Lot Riskier
3 Biotech Stocks That Are Getting a Heckuva Lot Riskier
Motley Fool
Ironwood Pharmaceuticals
Aegerion
MannKind
Flag link:
Companies Betting on the Next 10 Blockbuster Drugs
Companies Betting on the Next 10 Blockbuster Drugs
24/7WallStreet
Juxtapid
Otezla
Aegerion
Celgene
GW Pharma
Sativex
Intercept Pharma
OCA
Ironwood Pharmaceuticals
Linzess
Lpath
iSONEP
MannKind
Afrezza
Xtandi
H.P. Acthar Gel
Questcor Pharmaceuticals
eteplirsen
Sarepta Therapeutics
Flag link:
Why Ironwood Pharmaceuticals (IRWD) is Poised to Beat Earnings Estimates (Again)
Why Ironwood Pharmaceuticals (IRWD) is Poised to Beat Earnings Estimates (Again)
Yahoo/Zacks.com
earnings
Ironwood Pharmaceuticals
Flag link:
Previous Data Signals Positive Phase IIb Results Likely To Come For Synergy Pharmaceuticals
Previous Data Signals Positive Phase IIb Results Likely To Come For Synergy Pharmaceuticals
Seeking Alpha
Synergy Pharmaceuticals
IBS-C
Ironwood Pharmaceuticals
Linzess
Sucampo
plecanatide
Flag link:
Narrower-than-Expected Loss at Ironwood, Shares Up
Narrower-than-Expected Loss at Ironwood, Shares Up
Yahoo/Zacks.com
earnings
Ironwood Pharmaceuticals
Flag link:
5 Pharmas Spending the Most on Advertising to Physicians in Print Media
5 Pharmas Spending the Most on Advertising to Physicians in Print Media
Motley Fool
JNJ
Forest Labs
Pfizer
Novartis
Ironwood Pharmaceuticals
Flag link:
Ironwood Pharma 2Q loss widens, revenue slides
Ironwood Pharma 2Q loss widens, revenue slides
Yahoo/AP
earnings
Ironwood Pharmaceuticals
Flag link:
Ironwood commences first phase of anxiety drug trial in US
Ironwood commences first phase of anxiety drug trial in US
Pharmaceutical Business Review
Ironwood Pharmaceuticals
anxiety
IW-2143
Flag link:
10 Drugs Approved by the FDA in 2012 to Be Thankful For
10 Drugs Approved by the FDA in 2012 to Be Thankful For
Motley Fool
Xtandi
Medivation
prostate cancer
Stribild
Gilead Sciences
HIV
Belviq
Arena Pharmaceuticals
obesity
weight loss
Qsymia
Vivus
Kyprolis
ONYX Pharmaceuticals
Multiple Myeloma
Omontys
Affymax
anemia
Linzess
irritable bowel syndrome
Ironwood Pharmaceuticals
Bosulif
chronic myeloid leukemia
Pfizer
Amyvid
Alzheimer's disease
Eli Lilly
Eylea
macular degeneration
Regeneron
Flag link:

Pages